14 / 32
ESC 2016
27–31 AUGUST 2016
• ROME, ITALY
This year’s European
Society of Cardiology
(ESC) Congress saw
the presentation of
key studies such as the
DANISH, PRAGUE-16,
CE MARC 2, SAVE
and NACIAM trials.
PracticeUpdate
Cardiology
Advisory
Board member
Dr Deepak Bhatt lists
his top abstracts
from ESC 2016, while
Professor TomMarwick
and Professor Garry
Jennings share their
insights from the
meeting.
Dr Deepak Bhatt picks ASCOT,
EMPA-REG OUTCOME, FRISC
II and ANNEXA-4 as some of his
ESC 2016 top abstracts
Deepak Bhatt MD, MPH, FACC, FAHA, FSCAI, FESC is Executive
Director of Interventional Cardiovascular Programs at Brigham
and Women’s Hospital Heart & Vascular Center and Professor of
Medicine at Harvard Medical School.
Clinical trial update: prevention
The influence of blinding and un-blinding on
statin related adverse events: new evidence from
the Anglo-Scandinavian Cardiac Outcomes Trial
(ASCOT).
Presented by A Gupta
Clinical trial update: heart failure and
pacing
Effects of empagliflozin on cardiovascular
mortality by prevalent or incident heart failure
in EMPA-REG OUTCOME.
Presented by
D Fitchett
Effects of empagliflozin on overall heart failure
burden in EMPA-REG OUTCOME.
Presented
by D Fitchett
Clinical trial update: coronary artery
disease
A life-time perspective on the effects of an early
invasive compared with a non-invasive treatment
strategy in patients with non-ST-elevation acute
coronary syndrome – the FRISC II 15 years
follow-up.
Presented by L Wallentin
Hot line: prevention and lipids
A naturally randomised trial comparing the effect
of long-term exposure to lower LDL-C, lower
SBP, or both on the risk of cardiovascular disease.
Presented by BA Ference
Hot line: coronary artery disease
and imaging
AMERICA – Systematic detection
and management of multivascular
involvement of atherothrombosis in
coronary patients in comparison with
treatment of coronary disease only.
Presented by J-P Collet
Clinical trial update: platelet
therapy
Prevention of first stroke with ticagrelor
in patients with prior myocardial
infarction: insights from PEGASUS-
TIMI 54.
Presented by M Bonaca
Hot line: preventive strategies 2
ANNEXA-4 –Andexanet alfa for reversal
of Factor Xa inhibitors in patients with
acute major bleeding.
Presented by SJ
Connolly
Registries: miscellaneous
Optimal blood pressure in CAD patients:
is there a J-curve phenomenon? Insights
from 22,695 hypertensive CAD patients
in the CLARIFY registry.
Presented by
PG Steg
© ESC Congress 2016 – International Center for Documentary Arts (ICDA)
PRACTICEUPDATE CARDIOLOGY
EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS
14